https://www.selleckchem.com/pr....oducts/tinengotinib.
The dose of 0.06μg of protein proved to be effective versus the placebo by significantly reducing CSMS and increasing tolerance to the allergenic extract in the conjunctival provocation test, after the first pollen season. This group showed a significant reduction in specific IgE after the second pollen season relative to the baseline. There were no variations in IgG4 levels. Only one grade 2 systemic reaction was recorded. Intradermal immunotherapy with Ppratense allergoid has been shown to be effective and safe, reducing CSMS, in
Like
Comment
Share
